Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 641 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lacrimal Apparatus Disease Clear all
Completed Phase 4 Interventional

A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens

NCT01061268
View directory record Official record
Conditions
Dry Eye
Interventions
No topical artificial tear, Blink® Tears Lubricant Eye Drops
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

NCT01817582
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Lotemax, Restasis, Soothe® Lubricant Eye Drops
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
40 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease

NCT04498182
View directory record Official record
Conditions
Dry Eye Disease
Interventions
AR-15512 Ophthalmic Solution, AR-15512 Ophthalmic Solution Vehicle
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Not applicable Interventional Results available

Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator

NCT02526290
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
Intranasal Lacrimal Neurostimulator (Oculeve)
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 13, 2026, 8:09 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Ocular Surface Dry Eye Microbiome

NCT02306668
View directory record Official record
Conditions
Dry Eyes
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multi-Colored Placido Disk Viability

NCT02148497
View directory record Official record
Conditions
Dry Eye, Sjogren's Disease, Healthy
Interventions
Multi-colored Placido disk imaging
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 89 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 13, 2026, 8:09 AM EDT
Active, not recruiting Phase 3 Interventional

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214
View directory record Official record
Conditions
Sjogren Syndrome
Interventions
VAY736, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
23
States / cities
Fullerton, California • La Palma, California • Brandon, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Not applicable Interventional

Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD

NCT02621593
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
M22-IPL
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Beverly Hills, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 13, 2026, 8:09 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

NCT06964269
View directory record Official record
Conditions
Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis
Interventions
Acthar Gel 80 UNT/ML Injectable Solution
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 13, 2026, 8:09 AM EDT
Completed No phase listed Observational

Prevalence of Ocular Surface Disease in Glaucoma Patients

NCT00382122
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 13, 2026, 8:09 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
28
States / cities
Fullerton, California • La Palma, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 13, 2026, 8:09 AM EDT
Recruiting Phase 2 Interventional

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

NCT07281456
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Tofacitinib
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 8:09 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

NCT07548632
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Artificial Tear Run-in, licaminlimab, Vehicle of licaminlimab
Other · Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
14
States / cities
Aliso Viejo, California • Garden Grove, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting

NCT04649177
View directory record Official record
Conditions
Keratoconus, Ocular Surface Disease, Pellucid Marginal Corneal Degeneration, Ectasia, Corneal Trauma, Corneal Scar, Dry Eye Syndromes, Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions
Ocular surface optical coherence tomography
Device
Lead sponsor
Boston Sight
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Study of ST-100 as Treatment for Dry Eye Disease

NCT05241470
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ST-100 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Stuart Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Phase 4 Interventional Results available

Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

NCT05505292
View directory record Official record
Conditions
Dry Eye
Interventions
Lifitegrast 5% Ophthalmic Solution, Lifitegrast Ophthalmic Solution Vehicle
Drug · Other
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 13, 2026, 8:09 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction With FemtoSecond Laser

NCT01441895
View directory record Official record
Conditions
Cataract, Dry Eye
Interventions
Not listed
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Results available

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3

NCT03937882
View directory record Official record
Conditions
Dry Eye Syndromes, Dry Eye
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 13, 2026, 8:09 AM EDT
Terminated Phase 2 Interventional Results available

Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT02824913
View directory record Official record
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tear Lipid Layer Thickness With Emollient Eye Drops

NCT03380624
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Refresh Optive, Refresh Optive MEGA-3
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

NCT04556838
View directory record Official record
Conditions
Dry Eye
Interventions
VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief

NCT02455050
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Sodium Based Eye Drops, Systane® Gel Drops, Genteal® Lubricant Gel Drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 13, 2026, 8:09 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea

NCT01057147
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye
Interventions
rebamipide 2% ophthalmic suspension, placebo eye drops
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 13, 2026, 8:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Impairment of Reading Ability in Dry Eye Patients

NCT01826812
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
30 minutes sustained reading, Dry eye exam
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 13, 2026, 8:09 AM EDT